Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026
StockNews.AI · 2 hours
AI Summary
Alkermes reported Vibrance-2 phase 2 data for alixorexton in narcolepsy type 2, showing statistically significant improvements in wakefulness (MWT) and daytime sleepiness (ESS) at week eight across 10–18 mg doses, with benefits maintained through a 13-week open-label extension. The results bolster Alkermes' narcolepsy program and support global phase 3 development, potentially accelerating upside as Brilliance NT1/NT2 readouts approach.
Sentiment Rationale
Positive dual-endpoint results and sustained PROs in NT2 could de-risk the alixorexton program, supporting a higher multiple on the pathway to Phase 3 readouts and potential regulatory milestones; historical analogs show Phase 2 success often precedes modest near-term upside, followed by bigger moves on Phase 3 milestones.
Trading Thesis
ALKS could rally on NT2 success; phase 3 catalysts may unfold in 2026–2027.
Market-Moving
- ALKS stock may react to top-line Vibrance-2 NT2 results in the near term.
- MWT latency improved to ~14–16 minutes at higher doses, signaling meaningful wakefulness gains.
- ESS scores approached normal by week eight and remained improved at week 13.
- Global Brilliance phase 3 programs become a key near-term catalyst.
Key Facts
- Vibrance-2 NT2: alixorexton met dual primary endpoints for wakefulness and sleepiness.
- MWT improvements at week eight: 14 mg and 18 mg doses significant (p=0.049, 0.047).
- ESS improvements significant at 18 mg; week eight and week 13 scores approach normal.
- Open-label extension shows sustained wakefulness and normal ESS through week 13.
Companies Mentioned
- Alkermes plc (ALKS): Positive Vibrance-2 NT2 data strengthens alixorexton's growth narrative and supports global Phase 3 Brilliance program; potential near-term re-rating.
- Associated Professional Sleep Societies (APSS): Data were presented at APSS 40th annual meeting; event-driven visibility may influence sentiment but is not a direct price catalyst.
Industry News
Industry News. The release centers on a pivotal Phase 2 readout for a neuroscience asset, with clear implications for Alkermes' narcolepsy franchise and upcoming Phase 3 catalysts.